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Neurologist-in-training
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The aim of this section is to prepare the neuro- 
logist-in-training for the FMH examination, to
 confront her or him with specific problems of
everyday neurological practice and to give him 
or her updates on recent controversies in clinical
neurology. 
Neurological resident corner
Case vignette
The 60-year-old right-handed man, originating
from Serbia, was sent for a neurological con -
sultation because of a gait disorder. His son and
his ex-wife reported changes of his personality,
difficulties to articulate and a peculiar gait since
several years. Because of a depression he was in
ambulatory psychiatric care. He had lost 30 kilo-
grammes of body weight in the last 3 years 
and reported to have troubles to fall asleep. 
At the time of the first consultation, he had a
medication with diazepam 10 mg per day. Due
to his health problems, his relatives doubted 
that he could live alone in his apartment in the
future. At admission he was fully oriented, he
had an impaired short-term memory and was in
a depressive mood. Neurological examination
revealed no oculomotor abnormalities, no sen-
sory-motor deficits and a normal coordination.
Tendon reflexes were brisk, plantar responses
were flexor. Gait was broad based without clear
gait ataxia. There was a generalised hyperkine-
sia of limbs and to a lesser extent of the face 
and the trunk with sudden brisk movements
considered as choreatic movements.
Question 1
What are possible causes of a choreatic movement disorder?
Question 2
Which are the components of a chorea syndrome?
Question 3
What are symptomatic treatments of chorea?
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Table 1. Neurodegenerative chorea syndromes.
disorder inheritance chromosome gene phenotype
Huntington’s disease AD 4p16.3 huntingtin chorea syndrome
HDL1 AD 20pter-p12 prion-protein chorea syndrome
HDL2 AD 16q24.3 junctophilin-3 chorea syndrome
HDL3 AR 4p15.3 unknown chorea syndrome
HDL4 AR 6q27 TATA box-binding protein chorea syndrome 
SCA 17 ataxia
parkinsonism
dystonia
SCA1 AD 6p23 ataxin-1 chorea syndrome 
ataxia
slow saccades
polyneuropathy
DRPLA AD 12p13.31 atrophin-1 chorea syndrome 
ataxia
myoclonus epilepsy
choreo- AR 9q21 chorein chorea syndrome
acanthocytosis
erythrocyte acanthocytosis
(ChAc)
dystonia
parkinsonism
myopathy
axonal neuropathy
McLeod’s syndrome X-linked Xp21.2-p21.1 XK protein chorea syndrome
erythrocyte acanthocytosis
epilepsy
myopathy
cardiomyopathy
axonal neuropathy
benign hereditary AD 14q13 thyroid transcription isolated childhood-
chorea (BHC) factor-1 onset chorea
(For correct answers, see page 80)
Due to the history of the patient, a paraneo-
plastic chorea syndrome was suggested. Exten-
sive work-up including chest- and abdomen-
computed tomo graphy as well as determination
of anti-neuronal paraneoplastic antibodies was
negative. Blood smears did not reveal ery thro -
cyte acanthocytosis. Immunological evalua-
 tion including anti-double-stranded DNA anti -
bodies and anti-phospholipid  antibodies was
negative. Cerebral magnetic re sonance imaging
revealed a slight atrophy of the head of the 
caudate nucleus with consecutive  enlargement
of the lateral ventricles which is ob vious in 
the coronal sections but not necessarily in 
the axial sections (arrows, fig. 1A and 1B). 
FDG-positron emission tomography showed a
 severely impaired striatal FDG uptake. Because
of the negative evaluation of a symptomatic
chorea syndrome, a neurodegenerative chorea
syndrome was suspected. After appropriate  
ge netic counselling a molecular genetic ana -
lysis of the huntingtin gene was performed,
demonstrating 43 CAG repeats in the hunting -
tin gene.
Additional examinations
Huntington’s disease.
S C H W E I Z E R  A R C H I V  F Ü R  N E U R O L O G I E  U N D  P S Y C H I A T R I E w w w. a s n p . c h 1 6 0  n 2 / 2 0 0 979
Epicrisis
Treatment with tiapride (Tiapridal®) 3 × 100 mg
and mirtazepine (Remeron®) 1 × 30 mg was
 initiated. After 3 months sleep quality had con-
siderably improved, the choreatic movement
disorder was less pronounced, and he could still
live in his own apartment with minor support 
of relatives and the local social service.
Take-home message
fi A choreatic movement disorder may have
 different aetiologies including several
treatable entities.
fi A hereditary neurodegenerative chorea
syndrome may be present in the absence
of an obvious family history.
fi Although hereditary neurodegenerative
cho rea syndromes are relentlessly pro-
gressive fatal disorders, a symptomatic
treatment may be beneficial and can
 improve the quality of life of patients 
and relatives.
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Diagnosis
Answer 1
Choreatic movements may be the consequence of
an inflammatory alteration of the basal ganglia in
the context of a rheumatic fever, a systemic lupus
erythematodes or a phospholipid antibody syn-
drome. Rarely, choreatic movement disorders 
have been described as a paraneoplastic syndrome.
A choreatic movement disorder may arise as a 
side effect of medications such as neuroleptics.
Structural brain lesions of the striatum or the
 subthalamic nucleus such as an ischaemia hae mor-
r hage or a brain tumour may cause haemichorea 
or hemiballism. Tic disorders or psychogenic move-
ment disorders may have chorea-like features.
 Finally, a choreatic movement disorder may be a
symptom of a neurodegenerative chorea syndrome
(table 1).
Answer 2
Choreatic movement disorder
Chorea is the ancient Greek word for “dancing”. 
A choreatic movement disorder is defined as rapid,
irregular, spontaneous movements which arise
 accidently and  abruptly flow from one part of the
body to the other. Choreatic movement may be
 incorporated in voluntary movements such as in
the milkman grip sign.
Psychiatric manifestations
Psychiatric manifestations are frequent in chorea
syndromes and may precede motor or cognitive
manifestations. Psychiatric manifestations may in-
clude changes of personality, affective disorders,
obsessive-compulsive disorders as well as manic
and psychotic symptoms.
Cognitive decline
Cognitive dysfunction in chorea syndromes often
spares long-term memory but impairs executive
functions, such as organising, planning, checking 
or adapting alternatives, and delays the acquisition
of new motor skills. Anosognosia is often evident.
Answer 3
Choreatic movement disorders may be amelior -
ated by dopamine antagonists or dopamine delet -
ing drugs. First-line medications are dopamine
 antagonistic neuroleptics such as tiapride (Tia -
pridal®), 3 × 100 mg to 3 × 400 mg per day, or sulpi -
ride (Dogmatil®), 2 × 50 mg to 2 × 400 mg per day.
Other neuroleptic drugs with antichoreatic effect
are clozapine (Leponex®), 3 × 6.25 to 3 × 25 mg, 
or haloperidole (Haldol®), 3 × 0.5 to 3 × 2 mg.
Because of the high risk of tardive dyskinesias 
or other extrapyramidal side effects, however,
 haloperidole is reserved for severe, otherwise
 untreatable choreatic movement disorders. An
 alternative to the neuroleptic drugs is the dopa -
mine depleting drug tetrabenazine (Nitoman®), 
25 to 100 mg per day. A relevant possible adverse
effect is the development of a depression. Tetra -
benazine is not approved in Switzerland, but there
is an approval for the treatment of choreatic
 movement disorders in Germany. It may be pre-
scribed as an “orphan drug” for the treatment of 
a choreatic movement disorder after approval of
assumption of costs by the health insurance.
S C H W E I Z E R  A R C H I V  F Ü R  N E U R O L O G I E  U N D  P S Y C H I A T R I E w w w. s a n p . c h 1 6 0  n 2 / 2 0 0 980
Neurological resident corner
Neurologist-in-training
